121 related articles for article (PubMed ID: 38307578)
21. Dynamic monitoring of serum CEA and CA19-9 predicts the prognosis of postoperative stage II colon cancer.
Wang R; Xu B; Sun M; Pang X; Wang X; Zhu J; Lian J; Lu H
Eur J Surg Oncol; 2023 Dec; 49(12):107138. PubMed ID: 37925830
[TBL] [Abstract][Full Text] [Related]
22. The Prognostic Value of Preoperative Serum CEA and CA19-9 Values in Stage I-III Colorectal Cancer.
Wang RF; Song BR; Peng JJ; Cai GX; Liu FQ; Wang MH; Cai SJ; Ye X
Hepatogastroenterology; 2014 Jun; 61(132):994-9. PubMed ID: 26158155
[TBL] [Abstract][Full Text] [Related]
23. Trajectories of Perioperative Serum Tumor Markers and Colorectal Cancer Outcomes: A Retrospective, Multicenter Longitudinal Cohort Study.
Li C; Zhang D; Pang X; Pu H; Lei M; Fan B; Lv J; You D; Li Z; Zhang T
EBioMedicine; 2021 Dec; 74():103706. PubMed ID: 34801967
[TBL] [Abstract][Full Text] [Related]
24. Lymphocyte-to-monocyte ratio combined with CA19-9 for predicting postoperative recurrence of colorectal cancer in patients with diabetes.
Yu D; An G; Yao J
J Clin Lab Anal; 2021 Sep; 35(9):e23944. PubMed ID: 34418175
[TBL] [Abstract][Full Text] [Related]
25. Revisiting ab initio carcinoembryonic antigen and CA19-9 tumor markers in colorectal carcinoma in association with anatomotopographic location and staging of disease.
Lerch M; Sengul D; Sengul I; Peteja M; Přibylová L; Gawel W; Pelikán A; Tomaskova H; Malý T; Janout V
Rev Assoc Med Bras (1992); 2023; 69(9):e20230627. PubMed ID: 37729380
[TBL] [Abstract][Full Text] [Related]
26. CA19-9 is a significant prognostic marker of patients with stage III gastric cancer.
Kambara Y; Miyake H; Nagai H; Yoshioka Y; Shibata K; Asai S; Yuasa N
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1918-1924. PubMed ID: 32814681
[TBL] [Abstract][Full Text] [Related]
27. Identifying tumor markers-stratified subtypes (CA-125/CA19-9/carcinoembryonic antigen) in cervical adenocarcinoma.
Zhang Z; Li Y; Wu Y; Bi R; Wu X; Ke G; Zhu J
Int J Biol Markers; 2023 Dec; 38(3-4):223-232. PubMed ID: 37933442
[TBL] [Abstract][Full Text] [Related]
28. Identification of the Risk Factors for Recurrence of Stage III Colorectal Cancer.
Neki K; Eto K; Kosuge M; Ohkuma M; Ito D; Takeda Y; Yatabe S; Sugano H; Yanaga K
Anticancer Res; 2019 Oct; 39(10):5721-5724. PubMed ID: 31570473
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment Serum Carbohydrate Antigen 19-9 Concentration Is a Predictor of Survival of Patients Who Have Undergone Curative Resection of Stage IV Rectal Cancer.
Miki H; Akiyoshi T; Ogura A; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Noma H; Saiura A; Fukunaga Y; Ueno M
Dig Surg; 2018; 35(5):389-396. PubMed ID: 28858867
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Clinical Diagnostic and Prognostic Value of Preoperative Serum Carcinoembryonic Antigen, CA19-9, and CA24-2 for Colorectal Cancer.
Hou S; Jing J; Wang Y; Du L; Tian B; Xu X; Sun T; Shi Y
Altern Ther Health Med; 2023 Sep; 29(6):192-197. PubMed ID: 37295009
[TBL] [Abstract][Full Text] [Related]
32. Clinical Significance of Early Recurrence After Curative Resection of Colorectal Cancer.
Yamauchi N; Matsuda T; Sawad R; Hasegawa H; Yamashita K; Harada H; Urakawa N; Goto H; Kanaji S; Oshikiri T; Kakeji Y
Anticancer Res; 2022 Nov; 42(11):5553-5559. PubMed ID: 36288894
[TBL] [Abstract][Full Text] [Related]
33. Prediction models of colorectal cancer prognosis incorporating perioperative longitudinal serum tumor markers: a retrospective longitudinal cohort study.
Li C; Zhao K; Zhang D; Pang X; Pu H; Lei M; Fan B; Lv J; You D; Li Z; Zhang T
BMC Med; 2023 Feb; 21(1):63. PubMed ID: 36803500
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer.
Park IJ; Choi GS; Jun SH
Anticancer Res; 2009 Oct; 29(10):4303-8. PubMed ID: 19846991
[TBL] [Abstract][Full Text] [Related]
35. The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery.
Okamura R; Hasegawa S; Hida K; Hoshino N; Kawada K; Sugihara K; Sakai Y;
Int J Clin Oncol; 2017 Feb; 22(1):96-101. PubMed ID: 27503134
[TBL] [Abstract][Full Text] [Related]
36. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.
Ushigome M; Shimada H; Miura Y; Yoshida K; Kaneko T; Koda T; Nagashima Y; Suzuki T; Kagami S; Funahashi K
Int J Clin Oncol; 2020 Apr; 25(4):622-632. PubMed ID: 31820210
[TBL] [Abstract][Full Text] [Related]
37. [The value of NLR, FIB, CEA and CA19-9 in colorectal cancer].
Qian X; Wang H; Ren Z; Jin F; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Apr; 55(4):499-505. PubMed ID: 33858062
[No Abstract] [Full Text] [Related]
38. Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer.
Shibata C; Nakano T; Yasumoto A; Mitamura A; Sawada K; Ogawa H; Miura T; Ise I; Takami K; Yamamoto K; Katayose Y
BMC Surg; 2022 Jun; 22(1):213. PubMed ID: 35655198
[TBL] [Abstract][Full Text] [Related]
39. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
40. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
